BioSpace News Archive

At the first China International Import Expo, Sanofi, the world’s leading healthcare company, said during the China Health Road Symposium, that with Innovation, Partnership and Commitment as the three key words, it will strive to introduce the innovative drugs and vaccines exhibited at the import expo to China as early as possible.

Phase II data in NSCLC with bemcentinib/KEYTRUDA combination: First stage of trial in previously treated patients reported 40% ORR and ca. 6 months median PFS in AXL positive patients, stage 2 actively enrolling patients

Fuel & Toll Payments the First Big Wins for the Financial IoT

Swedish Orphan Biovitrum AB has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US.

Valens GroWorks Corp. is pleased to announce it will begin trading, at market open today, on the OTCQB® under the ticker symbol “MYMSF”. Quotes and market information are now available at: www.otcmarkets.com/stock/MYMSF/quote

Patient-centric drug delivery important for treatment adherence, commercial success

The Global Virus Network announced today the addition of the University of Nebraska Medical Center (UNMC), West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) at the University of Ghana and Colombia-Wisconsin One-Health Consortium (CWOHC) as its newest Centers of Excellence.

New centers give study near complete coverage of North American FPC sites in drive to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer

Earnings and business update call scheduled for 9:00 am ET today

Fully-automated BD Phoenix™ CPO Detect Test Receives U.S. FDA Clearance.